Jane Street Group LLC Buys 98,581 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Jane Street Group LLC increased its position in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 130.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,157 shares of the biotechnology company’s stock after buying an additional 98,581 shares during the quarter. Jane Street Group LLC owned 0.07% of Adaptimmune Therapeutics worth $166,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC increased its position in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares during the period. Baillie Gifford & Co. boosted its holdings in shares of Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after buying an additional 1,626,657 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics during the 3rd quarter worth approximately $95,000. Fullcircle Wealth LLC bought a new position in shares of Adaptimmune Therapeutics during the 3rd quarter worth approximately $33,000. Finally, Vontobel Holding Ltd. boosted its holdings in shares of Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after buying an additional 30,000 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ:ADAP opened at $0.60 on Tuesday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The stock has a market cap of $152.33 million, a PE ratio of -2.71 and a beta of 2.24. The stock’s fifty day simple moving average is $0.65 and its two-hundred day simple moving average is $0.91. Adaptimmune Therapeutics plc has a 1-year low of $0.53 and a 1-year high of $2.05.

Wall Street Analyst Weigh In

ADAP has been the topic of a number of research analyst reports. StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Mizuho cut their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. HC Wainwright cut their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Guggenheim cut their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $2.79.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.